Skip to main content
Erschienen in: Neurotoxicity Research 4/2021

01.08.2021 | Original Article

Botulinum Injections for Idiopathic Cervical Dystonia: a Longitudinal Study

verfasst von: Gilad Yahalom, Tsvia Fay-Karmon, Vered Livneh, Simon Israeli-Korn, Lilach Ephraty, Sharon Hassin-Baer

Erschienen in: Neurotoxicity Research | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Botulinum toxin (BT) injections into the cervical muscles are an effective and commonly practiced treatment approach for cervical dystonia. In this retrospective longitudinal study, we collected data from the Sheba electronic medical records on consecutive patients with idiopathic cervical dystonia (ICD), treated regularly with periodic BT injections between the years 2008–2020. All treatment visits were analyzed regarding type of toxin, dose injected, and clinical outcomes. The vast majority of patients were treated with abobotulinum toxin A. Sixty-four ICD patients (51 (79.7%) females, onset at age 45.8 ± 13.7 years) were treated over 17.1 ± 13.9 (range 3 to 49) visits per patient; BT treatment efficacy increased gradually from initial treatment sessions to visit 13, when it achieved a steady state. While the subjective report of percentage improvement and its duration were around 78.9 ± 17.1% for 2.8 ± 1.0 months, respectively, the dose of BT increased significantly over the years (p = 0.006). Side effects (SE) were not rare, and commonly recurred after subsequent sessions and were usually mild and short-lasting, with dysphagia being the most common (~17.5%), followed by neck/arm weakness (11.9%) and cervical pain (8.9%). Repeated injections of BT for ICD remain beneficial for patients over several years of therapy, and despite mild SE, patients tend to adhere to a 3–4 months interval schedule.
Literatur
Zurück zum Zitat Bentivoglio AR, Di Stasio E, Mulas D, Cerbarano ML, Ialongo T, Laurienzo A, Petracca M (2017) Long-term abobotulinumtoxin a treatment of cervical dystonia. Neurotox Res 32(2):291–300CrossRef Bentivoglio AR, Di Stasio E, Mulas D, Cerbarano ML, Ialongo T, Laurienzo A, Petracca M (2017) Long-term abobotulinumtoxin a treatment of cervical dystonia. Neurotox Res 32(2):291–300CrossRef
Zurück zum Zitat Butler JS, Beiser IM, Williams L, McGovern E, Molloy F, Lynch T, Healy DG, Moore H, Walsh R, Reilly RB, O’Riordan S, Walsh C, Hutchinson M (2015) age-related sexual dimorphism in temporal discrimination and in adult-onset dystonia suggests GABAergic mechanisms. Front Neurol 6:258CrossRef Butler JS, Beiser IM, Williams L, McGovern E, Molloy F, Lynch T, Healy DG, Moore H, Walsh R, Reilly RB, O’Riordan S, Walsh C, Hutchinson M (2015) age-related sexual dimorphism in temporal discrimination and in adult-onset dystonia suggests GABAergic mechanisms. Front Neurol 6:258CrossRef
Zurück zum Zitat Dressler D, Dirnberger G (2000) Botulinum toxin therapy: risk factors for therapy failure. Mov Disord 15(Suppl. 2):51 Dressler D, Dirnberger G (2000) Botulinum toxin therapy: risk factors for therapy failure. Mov Disord 15(Suppl. 2):51
Zurück zum Zitat Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 8:S92-100CrossRef Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 8:S92-100CrossRef
Zurück zum Zitat Felicio AC, Godeiro-Junior C, de Carvalho AP, Borges V, Silva SM, Ferraz HB (2009) Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia. Neurol Sci 30(4):291–294CrossRef Felicio AC, Godeiro-Junior C, de Carvalho AP, Borges V, Silva SM, Ferraz HB (2009) Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia. Neurol Sci 30(4):291–294CrossRef
Zurück zum Zitat Finsterer J, Maeztu C, Revuelta GJ, Reichel G, Truong D (2015) Collum-caput (COL-CAP) concept for conceptual anterocollis, anterocaput, and forward sagittal shift. J Neurol Sci 355(1–2):37–43CrossRef Finsterer J, Maeztu C, Revuelta GJ, Reichel G, Truong D (2015) Collum-caput (COL-CAP) concept for conceptual anterocollis, anterocaput, and forward sagittal shift. J Neurol Sci 355(1–2):37–43CrossRef
Zurück zum Zitat Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, Turkel C, BOTOX Poststroke Spasticity Study Group (2004) Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 63:1971–1973CrossRef Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, Turkel C, BOTOX Poststroke Spasticity Study Group (2004) Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 63:1971–1973CrossRef
Zurück zum Zitat Han V, Skorvanek M, Smit M, Turcanova Koprusakova M, Hoekstra T, van Dijk JP, Tijssen MAJ, Gdovinova Z, Reijneveld SA (2020) Prevalence of non-motor symptoms and their association with quality of life in cervical dystonia. Acta Neurol Scand 142(6):613–622CrossRef Han V, Skorvanek M, Smit M, Turcanova Koprusakova M, Hoekstra T, van Dijk JP, Tijssen MAJ, Gdovinova Z, Reijneveld SA (2020) Prevalence of non-motor symptoms and their association with quality of life in cervical dystonia. Acta Neurol Scand 142(6):613–622CrossRef
Zurück zum Zitat Hefter H, Schomaecker I, Schomaecker M, Samadzadeh S (2020) Disease progression of idiopathic cervical dystonia in spite of improvement after botulinum toxin therapy. Front Neurol 11:588395CrossRef Hefter H, Schomaecker I, Schomaecker M, Samadzadeh S (2020) Disease progression of idiopathic cervical dystonia in spite of improvement after botulinum toxin therapy. Front Neurol 11:588395CrossRef
Zurück zum Zitat Hvizdošová L, Nevrlý M, Otruba P, Hluštík P, Kaňovský P, Zapletalová J (2020) The prevalence of dystonic tremor and tremor associated with dystonia in patients with cervical dystonia. Sci Rep 10(1):1436CrossRef Hvizdošová L, Nevrlý M, Otruba P, Hluštík P, Kaňovský P, Zapletalová J (2020) The prevalence of dystonic tremor and tremor associated with dystonia in patients with cervical dystonia. Sci Rep 10(1):1436CrossRef
Zurück zum Zitat Jochim A, Meindl T, Mantel T, Zwirner S, Zech M, Castrop F, Haslinger B (2019) Treatment of cervical dystonia with abo- and onabotulinumtoxin A: long-term safety and efficacy in daily clinical practice. J Neurol 266(8):1879–1886CrossRef Jochim A, Meindl T, Mantel T, Zwirner S, Zech M, Castrop F, Haslinger B (2019) Treatment of cervical dystonia with abo- and onabotulinumtoxin A: long-term safety and efficacy in daily clinical practice. J Neurol 266(8):1879–1886CrossRef
Zurück zum Zitat Jost WH, Schramm A, Müngersdorf M, Stenner A, Schwingenschuh P, Maisonobe P, Koch M, Haslinger B (2019) Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study. J Neurol Sci 399:44–50CrossRef Jost WH, Schramm A, Müngersdorf M, Stenner A, Schwingenschuh P, Maisonobe P, Koch M, Haslinger B (2019) Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study. J Neurol Sci 399:44–50CrossRef
Zurück zum Zitat Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246(4):265–274 Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246(4):265–274
Zurück zum Zitat LaHue SC, Albers K, Goldman S, Lo RY, Gu Z, Leimpeter A, Fross R, Comyns K, Marras C, de Kleijn A, Smit R, Katz M, Ozelius LJ, Bressman S, Saunders-Pullman R, Comella C, Klingman J, Nelson LM, Van Den Eeden SK, Tanner CM (2020) Cervical dystonia incidence and diagnostic delay in a multiethnic population. Mov Disord 35(3):450–456CrossRef LaHue SC, Albers K, Goldman S, Lo RY, Gu Z, Leimpeter A, Fross R, Comyns K, Marras C, de Kleijn A, Smit R, Katz M, Ozelius LJ, Bressman S, Saunders-Pullman R, Comella C, Klingman J, Nelson LM, Van Den Eeden SK, Tanner CM (2020) Cervical dystonia incidence and diagnostic delay in a multiethnic population. Mov Disord 35(3):450–456CrossRef
Zurück zum Zitat Mejia NI, Vuong KD, Jankovic J (2005) Longterm botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20:592–597CrossRef Mejia NI, Vuong KD, Jankovic J (2005) Longterm botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20:592–597CrossRef
Zurück zum Zitat Misra VP, Ehler E, Zakine B, Maisonobe P, Simonetta-Moreau M, Interest In CD Group (2012) Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open 2(3):e000881CrossRef Misra VP, Ehler E, Zakine B, Maisonobe P, Simonetta-Moreau M, Interest In CD Group (2012) Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open 2(3):e000881CrossRef
Zurück zum Zitat Norris SA, Jinnah HA, Espay AJ, Klein C, Brüggemann N, Barbano RL, Malaty IA, Rodriguez RL, Vidailhet M, Roze E, Reich SG, Berman BD, LeDoux MS, Richardson SP, Agarwal P, Mari Z, Ondo WG, Shih LC, Fox SH, Berardelli A, Testa CM, Cheng FC, Truong D, Nahab FB, Xie T, Hallett M, Rosen AR, Wright LJ, Perlmutter JS (2016) Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord 31(12):1874–1882CrossRef Norris SA, Jinnah HA, Espay AJ, Klein C, Brüggemann N, Barbano RL, Malaty IA, Rodriguez RL, Vidailhet M, Roze E, Reich SG, Berman BD, LeDoux MS, Richardson SP, Agarwal P, Mari Z, Ondo WG, Shih LC, Fox SH, Berardelli A, Testa CM, Cheng FC, Truong D, Nahab FB, Xie T, Hallett M, Rosen AR, Wright LJ, Perlmutter JS (2016) Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord 31(12):1874–1882CrossRef
Zurück zum Zitat Ortiz RM, Scheperjans F, Mertsalmi T, Pekkonen E (2019) Comorbidity and retirement in cervical dystonia. J Neurol 266(9):2216–2223CrossRef Ortiz RM, Scheperjans F, Mertsalmi T, Pekkonen E (2019) Comorbidity and retirement in cervical dystonia. J Neurol 266(9):2216–2223CrossRef
Zurück zum Zitat Reichel G, Stenner A, Jahn A (2009) The phenomenology of cervical dystonia. Fortschr Neurol Psychiatr 77(5):272–277CrossRef Reichel G, Stenner A, Jahn A (2009) The phenomenology of cervical dystonia. Fortschr Neurol Psychiatr 77(5):272–277CrossRef
Zurück zum Zitat Simpson LL (1981) The origin, structure, and pharmacologic activity of botulinum toxin. Pharmacol Rev 33:155–188PubMed Simpson LL (1981) The origin, structure, and pharmacologic activity of botulinum toxin. Pharmacol Rev 33:155–188PubMed
Zurück zum Zitat Tinazzi M, Squintani GM, Bhatia KP, Segatti A, Donato F, Valeriani M, Erro R (2019) Pain in cervical dystonia: evidence of abnormal inhibitory control. Parkinsonism Relat Disord 65:252–255CrossRef Tinazzi M, Squintani GM, Bhatia KP, Segatti A, Donato F, Valeriani M, Erro R (2019) Pain in cervical dystonia: evidence of abnormal inhibitory control. Parkinsonism Relat Disord 65:252–255CrossRef
Zurück zum Zitat Tinazzi M, Erro R, Mascia MM, Esposito M, Ercoli T, Ferrazzano G, Di Biasio F, Pellicciari R, Eleopra R, Bono F, Bertolasi L, Barone P, Scaglione CLM, Pisani A, Altavista MC, Cotelli MS, Ceravolo R, Cossu G, Zibetti M, Moja MC, Girlanda P, Maderna L, Albanese A, Petracca M, Magistrelli L, Misceo S, Minafra B, Romano M, Squintani GM, Modugno N, Aguggia M, Cassano D, Castagna A, Morgante F, Berardelli A, Defazio G (2020) Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. J Neural Transm (Vienna) 127:1435–1439CrossRef Tinazzi M, Erro R, Mascia MM, Esposito M, Ercoli T, Ferrazzano G, Di Biasio F, Pellicciari R, Eleopra R, Bono F, Bertolasi L, Barone P, Scaglione CLM, Pisani A, Altavista MC, Cotelli MS, Ceravolo R, Cossu G, Zibetti M, Moja MC, Girlanda P, Maderna L, Albanese A, Petracca M, Magistrelli L, Misceo S, Minafra B, Romano M, Squintani GM, Modugno N, Aguggia M, Cassano D, Castagna A, Morgante F, Berardelli A, Defazio G (2020) Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. J Neural Transm (Vienna) 127:1435–1439CrossRef
Zurück zum Zitat Tomic S, Petkovic I, Pucic T, Resan B, Juric S, Rotim T (2016) Cervical dystonia and quality of life. Acta Neurol Belg 116(4):589–592CrossRef Tomic S, Petkovic I, Pucic T, Resan B, Juric S, Rotim T (2016) Cervical dystonia and quality of life. Acta Neurol Belg 116(4):589–592CrossRef
Zurück zum Zitat Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S (2010) Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16(5):316–323CrossRef Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S (2010) Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16(5):316–323CrossRef
Zurück zum Zitat Wöllner J, Weise D, Leplow B (2021) Subjective versus objective symptom intensities ratings in cervical dystonia and hemifacial spasm across a botulinum neurotoxin cycle. Brain Behav e02023 Wöllner J, Weise D, Leplow B (2021) Subjective versus objective symptom intensities ratings in cervical dystonia and hemifacial spasm across a botulinum neurotoxin cycle. Brain Behav e02023
Metadaten
Titel
Botulinum Injections for Idiopathic Cervical Dystonia: a Longitudinal Study
verfasst von
Gilad Yahalom
Tsvia Fay-Karmon
Vered Livneh
Simon Israeli-Korn
Lilach Ephraty
Sharon Hassin-Baer
Publikationsdatum
01.08.2021
Verlag
Springer US
Erschienen in
Neurotoxicity Research / Ausgabe 4/2021
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI
https://doi.org/10.1007/s12640-021-00378-2

Weitere Artikel der Ausgabe 4/2021

Neurotoxicity Research 4/2021 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.